Fulcrum Therapeutics Inc

NASDAQ:FULCUnited States

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

Contact Information

Headquarters

26 Landsdowne StreetCAMBRIDGE, MA, United States 02139

Phone

617-651-8851

Fax

302-655-5049

Executives

Independent Chairman of the Board

Kate Haviland

President, Chief Executive Officer, Principal Financial Officer, Director

Alex Sapir

Chief Financial Officer, Treasurer

Alan Musso

Executive Vice President - Patient Affairs

Mel Hayes

Chief Regulatory Affairs and Quality Assurance Officer

Heather Faulds